Evidence map›Paper›PMID 31591235›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer.

Catharina Hagerling, Hugo Gonzalez, Kiarash Salari, Chih-Yang Wang, Charlene Lin, Isabella Robles, Merel van Gogh, Annika Dejmek, Karin Jirström, Zena Werb

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Histone acetylation modulators in breast cancer.Breast cancer research : BCR · 2025
    Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Catharina HagerlingDepartment of Anatomy, University of California, San Francisco, CA 94143-0452; catharina.hagerling@med.lu.se zena.werb@ucsf.edu.
Hugo GonzalezDepartment of Anatomy, University of California, San Francisco, CA 94143-0452.
Kiarash SalariDepartment of Anatomy, University of California, San Francisco, CA 94143-0452.
Chih-Yang WangDepartment of Anatomy, University of California, San Francisco, CA 94143-0452.
Charlene LinDepartment of Anatomy, University of California, San Francisco, CA 94143-0452.
Isabella RoblesDepartment of Anatomy, University of California, San Francisco, CA 94143-0452.
Merel van GoghDepartment of Anatomy, University of California, San Francisco, CA 94143-0452.
Annika DejmekDepartment of Translational Medicine, Lund University, Malmö SUS, SE-214 21 Malmö, Sweden.
Karin JirströmDepartment of Clinical Sciences, Division of Clinical Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden.
Zena WerbDepartment of Anatomy, University of California, San Francisco, CA 94143-0452; catharina.hagerling@med.lu.se zena.werb@ucsf.edu.ORCID 0000-0002-6525-3872
University of California, San Francisco · USLund University · SE

Funding

Role of Metalloproteinases in Mammary Gland RemodelingR01CA057621 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 1993 to 2017
$9.0M
Integrative approach to heterogeneity in breast cancer metastasisU01CA199315 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI, SPELLMAN, PAUL T. · 2016 to 2020
$3.2M
Role of GATA3 in transcriptional pathways suppressing breast cancer metastasisR01CA190851 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2015 to 2019
$2.0M
(PQC4) Fate of cells disseminating from human breast cancer xenograftsR01CA180039 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2013 to 2016
$1.3M
NCI NIH HHS R01 CA057621NCI NIH HHS R01 CA180039NCI NIH HHS R01 CA190851NCI NIH HHS U01 CA199315
6 · The paper itself

Abstract

Metastatic behavior varies significantly among breast cancers. Mechanisms explaining why the majority of breast cancer patients never develop metastatic outgrowth are largely lacking but could underlie the development of novel immunotherapeutic target molecules. Here we show interplay between nonmetastatic primary breast cancer and innate immune response, acting together to control metastatic progression. The primary tumor systemically recruits IFNγ-producing immune effector monocytes to the lung. IFNγ up-regulates

Indexed as

AnimalsCell Line, TumorCytotoxicity, ImmunologicFemaleImmunity, InnateImmunotherapyInterferon-gammaMammary Neoplasms, AnimalMembrane ProteinsMiceMice, Inbred BALB CMice, Inbred NODMice, SCIDMonocytesNeoplasm MetastasisNeutrophilsIFNG protein, mouseInterferon-gammaMembrane ProteinsSting1 protein, mouseSTING ProteinCCL2CCR2immune effector monocytesmetastatic breast cancerSTING

Identifiers

PMID31591235
PMCPMC6815161
OpenAlexW2979892275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.